ReviewJournal of hepatocellular carcinoma2026
Tumor-Associated Macrophages in Hepatocellular Carcinoma: From Ontogeny and Heterogeneity to Immune Evasion and Therapeutic Targeting.
Review in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer morbidity and mortality worldwide and typically arises within a profoundly immunosuppressive tumor microenvironment (TME). Among the myeloid populations that infiltrate the HCC microenvironment, tumor-associated macrophages (TAMs) are numerically dominant and function as central orchestrators of tumor initiation, progression, and immune evasion. TAMs originate from both tissue-resident Kupffer cells and bone marrow-derived monocytes, and are shaped by TME-derived cues such as hypoxia, metabolic stress, and inflammatory mediators that polarize them toward a tumor-promoting, M2-like phenotype. Once activated, TAMs release pro-angiogenic and trophic factors that sustain vascular remodeling and tumor proliferation, and they induce epithelial-mesenchymal transition (EMT) and stemness-associated programs that facilitate invasion and metastasis. Concomitantly, TAMs suppress antitumor immunity through the secretion of immunosuppressive cytokines such as IL-10 and TGF-β, the expression of PD-L1, and the recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). Clinically, a high density of TAM infiltration is strongly associated with aggressive disease features, early recurrence, and poor prognosis. Given their dual roles in promoting immune escape and therapeutic resistance, TAMs have emerged as critical nodes within the HCC ecosystem and as promising targets for translational intervention. This review summarizes current understanding of TAM ontogeny, phenotypic diversity, and functional heterogeneity in HCC, delineates the molecular and immunological mechanisms through which they drive tumor progression, and discusses emerging TAM-targeted therapeutic strategies with clinical potential including CSF1R inhibition, CD47-SIRPα blockade, and chimeric antigen receptor-macrophage (CAR-M) therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.